Lyell Immunopharma, Inc. /
ImmPACT Bio USA Inc.
Lyell Immunopharma completes ImmPACT Bio acquisition
What happened
Lyell Immunopharma, Inc. completed its acquisition of ImmPACT Bio USA Inc. on Oct. 31, 2024.
The consideration included $30.0 million in cash, adjusted for ImmPACT’s existing cash balance, and 37.5 million shares of Company Common Stock. Contingent consideration includes potential additional shares and a royalty on future U.S. sales.
The source
Everything on this page comes from the source below.
Lyell Immunopharma completes ImmPACT Bio acquisition
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly